Rat Recombinant Monoclonal EBNA2 antibody. Carrier free. Suitable for IP, WB and reacts with Human samples.
pH: 7.2 - 7.4
Constituents: 100% PBS
IP | WB | ICC | |
---|---|---|---|
Human | Tested | Tested | Not recommended |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Plays a key role in the activation of the host resting B-cell and stimulation of B-cell proliferation. Acts by up-regulating the expression of viral EBNA1-6, LMP1, LMP2A and LMP2B genes, as well as several host genes including CD21, CD23 and MYC. Activates transcription by acting as an adapter molecule that binds to cellular sequence-specific DNA-binding proteins such as host CBF1, SMARCB1 and SPI1. Once EBNA2 is near promoter sites, its acidic activating domain recruits basal and activation-associated transcription factors TFIIB, TAF40, TFIIH components ERCC2 and ERCC3, and CBP in order to promote transcription. Alternatively, EBNA2 can affect activities of cell cycle regulators and retard cell cycle progression at G2/M phase. It also induces chromosomal instability, by disrupting mitotic checkpoints, multi-nucleation and formation of micronuclei in infected cells (By similarity).
BYRF1, EBNA2, Epstein-Barr nuclear antigen 2, EBNA-2, EBV nuclear antigen 2
Rat Recombinant Monoclonal EBNA2 antibody. Carrier free. Suitable for IP, WB and reacts with Human samples.
pH: 7.2 - 7.4
Constituents: 100% PBS
ab255784 is the carrier-free version of Anti-EBNA2 antibody [R3] ab252828
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. The carrier-free buffer and high concentration allow for increased conjugation efficiency.
This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.
EBNA2 also known as the Epstein-Barr virus nuclear antigen 2 (EBNA-2) plays a critical role in viral protein function. It is a transcriptional activator essential for the latent infection cycle of Epstein-Barr virus (EBV). EBNA2 binds to specific DNA sequences and interacts with other host cellular factors to initiate transcription. The molecular mass of EBNA2 typically is approximately 88 kDa. EBNA2 mainly expresses in EBV-infected B lymphocytes where it contributes to their immortalization and proliferation.
EBNA2 is pivotal in the activation of several viral and cellular genes. It forms complexes with other proteins including the cellular transcription factor RBP-Jκ part of the Notch signaling pathway. This interaction is important for altering the expression patterns of both host and viral genes causing changes in the cell cycle and promoting latency. EBNA2 also regulates genes involved in immune response modulation aiding in viral persistence within the host by evading immune surveillance.
EBNA2 impacts transcriptional regulation and cell signaling reversibly. It is integral to the Notch signaling and transcriptional activation pathway related to EBV latency. EBNA2 recruits proteins like CBF1 (RBP-Jκ) a transcription factor that helps mediate cell fate decisions and maintain latency. It modulates pathways involving c-MYC a central regulator of cell growth and influences transcriptional activity with a downstream effect on cellular transformation and proliferation.
EBNA2 is prominently associated with EBV-related malignancies such as Burkitt's lymphoma and Hodgkin's lymphoma. These cancers arise partly from the dysregulated cellular growth induced by EBNA2-mediated transcriptional changes. In these disorders EBNA2 may interact with proteins like LMP1 another EBV-encoded protein that aids in the transformation process promoting oncogenesis and affecting therapy resistance mechanisms.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
This data was developed using Anti-EBNA2 antibody [R3] ab252828, the same antibody clone in a different buffer formulation.
Blocking and diluting buffer and concentration: 5% NFDM/TBST
The expression profile/ molecular weight observed is consistent with what has been described in the literature (PMID:8383171).
Exposure time: 10 seconds
All lanes: Western blot - Anti-EBNA2 antibody [R3] (Anti-EBNA2 antibody [R3] ab252828) at 1/1000 dilution
Lane 1: Raji (human Burkitts lymphoma B lymphocyte), whole cell lysate at 20 µg
Lane 2: HeLa (human epithelial cell line from cervix adenocarcinoma), whole cell lysate at 20 µg
All lanes: Western blot - Goat Anti-Rat IgG H&L (HRP) (Goat Anti-Rat IgG H&L (HRP) ab205720) at 1/5000 dilution
Predicted band size: 53 kDa
Observed band size: 75 kDa
This data was developed using Anti-EBNA2 antibody [R3] ab252828 the same antibody clone in a different buffer formulation.
EBNA2 was immunoprecipitated from 0.35 mg Raji (human Burkitt's lymphoma B lymphocyte) whole cell lysate 10ug with Anti-EBNA2 antibody [R3] ab252828 at 1/30 dilution (2ug in 0.35mg lysates). Western blot was performed on the immunoprecipitate using Anti-EBNA2 antibody [R3] ab252828 at 1/1000 dilution. Goat Anti-Rat IgG (H+L), HRP) (Goat Anti-Rat IgG H&L (HRP) ab205720) was used at 1/5000 dilution.
Lane 1: Raji (human Burkitt's lymphoma B lymphocyte) whole cell lysate 10ug
Lane 2: Anti-EBNA2 antibody [R3] ab252828 IP in Raji whole cell lysate
Lane 3: Rat monoclonal IgG2a (Rat IgG2a, kappa monoclonal [RTK2758] - Isotype Control ab18450) instead of Anti-EBNA2 antibody [R3] ab252828 in Raji whole cell lysate
Blocking and dilution buffer and concentration: 5% NFDM/TBST.
Exposure time: 3 seconds
All lanes: Immunoprecipitation - Anti-EBNA2 antibody [R3] (Anti-EBNA2 antibody [R3] ab252828)
Predicted band size: 53 kDa
Observed band size: 75 kDa
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com